Published in the Official Gazette, the AIFA determines the methods of use and the conditions of administration of the Merck anti-viral pill for the treatment of Covid "in adult patients not hospitalized for Covid 19 with recent onset mild-moderate disease and conditions concomitant clinics that represent specific risk factors ".
"The prescription and treatment - reads the determination - must guarantee the administration of the product as early as possible with respect to the onset of symptoms and in any case no later than 5 days from the beginning of the same".
(HANDLE).
